Research Topics
| Sarah E PinderSummaryAffiliation: University of Nottingham Country: UK Publications
| Collaborators
|
Detail Information
Publications
Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for managementSarah E Pinder
Department of Histopathology, Addenbrooke s Hospital, Cambridge, United Kingdom
Pathology 39:208-16. 2007..This review provides an update on the histological diagnosis of lobular neoplasia and columnar cell lesions and outlines recent clinico-pathological and molecular findings with discussion on clinical management...- The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classificationSarah E Pinder
University of Nottingham and Nottingham City Hospital NSH Trust, Nottingham, UK
Breast Cancer Res 5:254-7. 2003..The current definitions, histological features, and system of classification of ADH and DCIS are described in this manuscript... - Successful management of elderly breast cancer patients treated without radiotherapyKalliope Valassiadou
Division of Breast Surgery, University of Nottingham, Nottingham, UK
World J Surg Oncol 5:62. 2007..The addition of RT to surgery might constitute an imposition to such patients due to age-related factors. The aim of this study was to assess the efficacy of BCS without adjuvant RT in this group of patients... - Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breastZsolt Hodi
Department of Histopathology, Nottingham University Hospitals, Nottingham, UK
Histopathology 56:573-80. 2010..Shave sections assess a larger surface area of margin than radial sections. The aim was to assess the value of additional shave sections of the margin... - Selective use of post-mastectomy flap irradiation in high-risk breast cancer patientsKristjan S Asgeirsson
The Nottingham Breast Institute, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
Breast 14:298-303. 2005..The chest wall recurrence rate was 2.7% in those treated with radiotherapy. A low rate of local recurrence has been achieved with selective use of mastectomy flap radiotherapy... - Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?Zahra Madjd
CRC Academic Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
Cancer Immunol Immunother 54:149-56. 2005..This may suggest that CD46 alone can protect from complement lysis but that loss of CD55 and CD59 are associated with other roles in immune regulation... - Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breastFrances P O'Malley
Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
Mod Pathol 19:172-9. 2006..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria... - Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinomaGavin C Harris
Department of Histopathology, Nottingham City Hospital, UK
Am J Surg Pathol 27:11-5. 2003..However, in those patients in whom preoperative assessment of prognostic factors is most likely to be beneficial, i.e., those with grade 3 carcinomas, a high level of agreement was achieved in this large study... - Non-operative breast pathologySarah E Pinder
J Clin Pathol 60:1297-9. 2007 - MYC amplification in breast cancer: a chromogenic in situ hybridisation studyS Maria Rodriguez-Pinilla
The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
J Clin Pathol 60:1017-23. 2007.... - Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysisThomas C Putti
Department of Pathology, National University of Singapore, Singapore
Mod Pathol 18:26-35. 2005.... - An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerAndrew E Teschendorff
Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Genome Biol 8:R157. 2007..Reliable identification of ER-negative tumors that have a good prognosis is not yet possible... - An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breastBarbara Dunne
Department of Pathology, City Hospital, Nottingham, United Kingdom
Hum Pathol 34:1009-15. 2003..In our hands, 34betaE12 was the CK most frequently expressed in sarcomatoid areas in MSCs... - Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer?Andrew J Evans
Breast Institute, Nottingham International Breast Education Center and Nottingham City Hospital, Hucknall Rd, Nottingham NG5 1PB, United Kingdom
AJR Am J Roentgenol 187:1377-80. 2006..CONCLUSION: Mammographic spiculation is an independent, good prognostic factor for screening-detected invasive breast cancer. The mechanism of how mammographic spiculation confers a beneficial prognostic effect is not clear... - Reproducibility of cancer diagnosis using hairKeith D Rogers
Int J Cancer 118:1060; author reply 1061-2. 2006 - High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistryEmad A Rakha
The Breast Unit, Department of Histopathology, Nottingham City Hospital, University of Nottingham, United Kingdom
Int J Cancer 114:720-9. 2005..Although our results support E-cadherin as the TSG in invasive lobular carcinoma, they argue against the candidacy of E2F-4, CTCF, TRF2, P-cadherin, Ksp-cadherin and VE-cadherin as TSGs in breast cancer... - A consensus prognostic gene expression classifier for ER positive breast cancerAndrew E Teschendorff
Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Center, Hills Road, Cambridge CB2 2XZ, UK
Genome Biol 7:R101. 2006..A consensus prognostic gene expression classifier is still elusive in heterogeneous diseases such as breast cancer... - Loss of CD55 is associated with aggressive breast tumorsZahra Madjd
Cancer Research UK Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
Clin Cancer Res 10:2797-803. 2004..CD55 is overexpressed on some tumor cell lines, and in colorectal carcinomas, it has been shown to be an indicator of poor prognostic... - High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancerSuet F Chin
Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
Genome Biol 8:R215. 2007..To date, most genome-wide array comparative genomic hybridization studies have used tumor panels of relatively large tumor size and high Nottingham Prognostic Index (NPI) that are not as representative of breast cancer demographics... - Diagnostic, predictive and prognostic breast pathology. EditorialSarah E Pinder
Professor of Breast Pathology, Kings College London, Department of Academic Oncology, 3rd Floor Thomas Guy House, Guy's Hospital, St Thomas Street, London SE1 9RT, UK
Histopathology 52:1-2. 2008 - Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysisPeter T Simpson
Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
Am J Surg Pathol 29:734-46. 2005..These data further support the hypothesis that CCLs are a nonobligate, intermediary step in the development of some forms of low grade in situ and invasive carcinoma... - Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancerMichael A Gonzalez
Medical Research Council Cancer Cell Unit, Hutchison Medical Research Council Research Centre, Hills Rd, Cambridge CB2 2XZ, United Kingdom
J Clin Oncol 21:4306-13. 2003..To test the hypothesis that prognostic information in breast cancer may be derived from an accurate assessment of epithelial cell cycle entry, as indicated by expression of minichromosome maintenance (MCM) proteins. Materials and.. - Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progressionMichael A Gonzalez
Medical Research Council Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK
J Pathol 204:121-30. 2004..It is suggested that this explains its unexpected value as a prognostic marker in breast cancer... - Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosisEmad A Rakha
Department of Histopathology, Nottingham City Hospital, University of Nottingham, UK
J Pathol 203:754-61. 2004..E2F-4 appears to have an oncogenic role rather than a tumour suppressor role in breast carcinogenesis and, hence, it is not the gene targeted by 16q22.1 loss in breast carcinoma... - Total loss of MHC class I is an independent indicator of good prognosis in breast cancerZahra Madjd
Cancer Research UK Academic Unit of Clinical Oncology, Nottingham City Hospital, United Kingdom
Int J Cancer 117:248-55. 2005..001), tumour grade (p = 0.005) and intensity of MHC Class I light and heavy chains expression were shown to be independent prognostic factors predictive of overall survival (p-values HC10 = 0.047 and beta2m = 0.018)... - Non-operative breast pathology: lobular neoplasiaJorge S Reis-Filho
The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
J Clin Pathol 60:1321-7. 2007..Furthermore, the current recommendations for the management of lobular neoplasia diagnosed on core needle biopsies proposed in the National Health Service Breast Cancer Screening guidelines are discussed... - Expression of luminal and basal cytokeratins in human breast carcinomaDalia M Abd El-Rehim
Department of Histopathology, Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, UK
J Pathol 203:661-71. 2004..These findings provide further evidence that breast cancer has distinct differentiation subclasses that have both biological and clinical relevance... - Upregulation of MICA on high-grade invasive operable breast carcinomaZahra Madjd
Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom
Cancer Immun 7:17. 2007..Our results suggest that induced expression of MICA may be an indicator of poor prognosis in breast carcinoma and is indicative of a tumour environment that has undergone stresses such as apoptosis, necrosis, or hypoxia... - High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesDalia M Abd El-Rehim
Department of Histopathology, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Nottingham, United Kingdom
Int J Cancer 116:340-50. 2005..These observations could form the basis of revision of existing traditional classification systems for breast cancer... - Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic IndexGrace M Callagy
Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
Clin Cancer Res 12:2468-75. 2006..We validated the results in an independent series. Experimental Design and.. - Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?Raj S Rampaul
Clin Cancer Res 10:2578. 2004 - HER2 status in breast cancer--an example of pharmacogenetic testingMark Kroese
Consultant in Public Health Medicine, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
J R Soc Med 100:326-9. 2007..Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed...